S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
OTCMKTS:IDRSF

Idorsia (IDRSF) Stock Price, News & Analysis

$1.65
0.00 (0.00%)
(As of 03/1/2024 ET)
Today's Range
$1.65
$1.65
50-Day Range
$1.40
$2.60
52-Week Range
$1.40
$13.60
Volume
N/A
Average Volume
2,457 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

IDRSF stock logo

About Idorsia Stock (OTCMKTS:IDRSF)

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant), available in 25 and 50 mg, for the treatment of adult patients with insomnia. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

IDRSF Stock Price History

IDRSF Stock News Headlines

Viatris, Idorsia Announce Global Research And Development Collaboration
Here's what to expect from Idorsia's earnings
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Idorsia Shares Fall on Funding Needs
Idorsia reacquires the world-wide rights to aprocitentan
Idorsia Ltd (IDIA.SW)
Are Investors Undervaluing Idorsia Ltd (VTX:IDIA) By 38%?
Idorsia: Restructuring In Place
See More Headlines
Receive IDRSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Idorsia and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:IDRSF
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Jean-Paul Clozel M.D. (Age 69)
    CEO & Executive Director
    Comp: $1.57M
  • Mr. André C. Muller (Age 61)
    Executive VP & CFO
  • Dr. Martine Clozel (Age 69)
    Executive VP & Chief Scientific Officer
  • Mr. Andrew C. Weiss (Age 56)
    Senior VP and Head of Investor Relations & Corporate Communications
  • Mr. Julien Gander L.L.M. (Age 45)
    Senior VP, Group General Counsel & Company Secretary
  • Mr. Alexander Khatuntsev (Age 46)
    Senior VP & Head of Global Human Resources
  • Dr. Guy Braunstein M.D. (Age 68)
    Executive VP & Chief Medical Officer
  • Mr. Olivier Lambert (Age 58)
    Senior VP & Head of Technical Operations
  • Mr. Markus A. Riederer (Age 62)
    Senior VP & Head of Drug Discovery Biology
  • Mr. Christoph Boss (Age 56)
    Senior VP & Head of Drug Discovery Chemistry














IDRSF Stock Analysis - Frequently Asked Questions

Should I buy or sell Idorsia stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Idorsia in the last twelve months. There are currently 4 sell ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "strong sell" IDRSF shares.
View IDRSF analyst ratings
or view top-rated stocks.

How have IDRSF shares performed in 2024?

Idorsia's stock was trading at $2.45 at the beginning of 2024. Since then, IDRSF stock has decreased by 32.7% and is now trading at $1.65.
View the best growth stocks for 2024 here
.

How do I buy shares of Idorsia?

Shares of IDRSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:IDRSF) was last updated on 3/3/2024 by MarketBeat.com Staff